ScreenerHero

0H8TAclaris Therapeutics, Inc.

LSE · GB · Healthcare · Biotechnology · aclaristx.com
6.440USD+2.88%Mkt Cap: —P/E: —

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company produ…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap—
Enterprise Value831.76M $
Revenue (TTM)8.22M $
Gross Profit-62.27M $
Net Income (TTM)-75.74M $
Revenue/Share0.0640 USD
Last Price6.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-9.72
EV/Revenue101.20
P/S—
P/B7.00
EPS (TTM)-1.36
EPS (Forward)—
52W Range
5.88790% of range6.500
52W High6.500 USD
52W Low5.887 USD
Profitability
Gross Margin0.00%
Oper. Margin-1469.49%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.10%
ROA-28.98%
Growth
Revenue Growth-8.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.06M $
CapEx (TTM)—
FCF Margin-510.65%
FCF Yield—
Net Debt-89.71M $
Net Debt/EBITDA1.05
Balance Sheet
Debt/Equity1.49
Current Ratio3.46
Quick Ratio3.46
Book Value/Sh0.8910 USD
Cash/Share0.6220 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.40.94M
Float109.90M
Insiders2.18%
Institutions81.39%
Technical
SMA 501.202 (+435.6%)
SMA 2004.306 (+49.6%)
Beta0.78
S&P 52W Chg18.16%
Avg Vol (30d)1.29K
Avg Vol (10d)14.01K
Technical Indicators
RSI (14)70.3
MACD0.3791
MACD Signal0.3096
MACD Hist.+0.0696
BB Upper6.462 USD
BB Middle5.586 USD
BB Lower4.710 USD
BB Width31.37%
ATR (14)0.3152 USD
Vol Ratio (20d)0.12x